Diagnostics Pipeline: Savara Introduces Blood Test to Detect aPAP, a Rare Lung Disorder
Savara’s ClearPath assay needs just a few drops of blood to test for aPAP, a condition that can be difficult and invasive to diagnose
Emerging Tests-dtet
Image-Based AI Touted as a New Weapon Against Rare Cancers
Studies by Paige demonstrate the greater accuracy that artificial intelligence potentially offers for pathologists
Diagnostics Pipeline: Roche’s New Cobas Liat Panel Can Test for Multiple STIs Simultaneously
The PCR-driven test provides results in about 20 minutes in non-laboratory settings
New and Improved: The Latest Research in Disease Screening
New ideas and innovations look beyond conventional screening options to facilitate improved disease diagnosis and patient outcomes
Generalizing Genomics Learning
A new NIH network aims to remove barriers and share knowledge to drive more widespread adoption of genomics in clinical settings
When Is Genome Sequencing Advisable?
With patient and provider demand for WGS on the rise, what should laboratorians know about ordering and interpreting this testing?
Computing the Future of the Lab
Computational biology expert Keaun Amani shares his advice and insights on AI and machine learning tools for the clinical lab
Dissecting the Data Behind Healthcare AI
How do the underlying datasets affect artificial intelligence tools’ performance in the lab—and beyond?
Has Your AI Been Validated?
Many artificial intelligence-based medical devices have not undergone clinical validation—but what does this mean for the lab?
Removing Restrictions to Germline Testing
With the global cancer burden growing, is a universal germline genomic testing approach the key to more effectively combating the disease?
PGx Testing: First, Do No Harm
Recent advances in pharmacogenomic testing—and their role in ensuring safe, effective treatment selection for precision oncology
The Demand for Digital Pathology
When it comes to cancer, patients’ greatest fear is diagnostic delays—and they believe digital pathology and AI can reduce those delays
Syndromes Without a Name Bring Labs an Uphill Battle
In an era when genetic and genomic testing are theoretically affordable and accessible, why do so many patients remain undiagnosed?
